{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=13", "query": { "intervention": "monoclonal antibody CD20", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 426, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=monoclonal+antibody+CD20&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:53:52.661Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03562975", "title": "Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Pathologic Processes", "Demyelinating Diseases", "Nervous System Diseases", "Autoimmune Diseases", "Immune System Diseases", "Primary Progressive Multiple Sclerosis", "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2018-07-23", "completion_date": "2023-01-11", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562975" }, { "nct_id": "NCT02320292", "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ann Arbor Stage I Grade 1 Follicular Lymphoma", "Ann Arbor Stage I Grade 2 Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Yttrium Y-90 Ibritumomab Tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-02-11", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320292" }, { "nct_id": "NCT00166439", "title": "Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 50, "start_date": "2005-03", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00166439" }, { "nct_id": "NCT02003222", "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 488, "start_date": "2014-05-19", "completion_date": "2027-02-25", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 531, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003222" }, { "nct_id": "NCT01165112", "title": "Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2010-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165112" }, { "nct_id": "NCT01578707", "title": "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ofatumumab", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 391, "start_date": "2012-06", "completion_date": "2018-10-25", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 25, "location_summary": "La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578707" }, { "nct_id": "NCT05886036", "title": "Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nodular Lymphocyte Predominant B-Cell Lymphoma", "Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma", "Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2024-01-23", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 36, "location_summary": "Duarte, California • Aventura, Florida • Coral Gables, Florida + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05886036" }, { "nct_id": "NCT05303792", "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 68, "start_date": "2023-06-09", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303792" }, { "nct_id": "NCT00004040", "title": "Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "1998-06", "completion_date": "1999-06", "has_results": false, "last_update_posted_date": "2015-08-19", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 3, "location_summary": "Newport Beach, California • Knoxville, Tennessee • Bryan, Texas", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Bryan", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004040" }, { "nct_id": "NCT00073918", "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "iodine I 131 tositumomab", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 111, "start_date": "1999-02", "completion_date": "2011-10-02", "has_results": true, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-14T13:53:52.661Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073918" } ] }